JAMA vs The Lancet 2026: Impact Factor, Acceptance Rate & How to Choose

JAMA's editorial mandate: inform practicing physicians with clear, readable evidence that changes clinical decisions. The AMA has published JAMA since 1883, and the editorial identity reflects that mission, broad clinical medicine aimed at the doctor who needs to know what to do Monday morning.

JAMA's sweet spot:

• Comparative effectiveness studies that answer "which treatment should I use?"

• Health-services and implementation research showing how evidence translates to practice

• Clinical trials with direct implications for US medical practice (and generalizable beyond)

• Disparities research with clear patient-care implications

• Public health studies framed as clinical decisions

JAMA is explicit about protocols and statistical analysis plans. Study protocols with statistical analysis plans are required for clinical trials, and analyses should be consistent with the protocol and plan or described as post hoc. If your trial protocol says one thing and your paper says another, expect questions. This is a strength if your statistics are rock-solid and a hazard if they're not.

The JAMA Network ecosystem. JAMA is one of 13 journals in the JAMA Network, which includes specialty journals (JAMA Oncology, JAMA Cardiology, JAMA Internal Medicine, etc.) and JAMA Network Open (fully OA; an APC is required, see the JAMA Network access page for the current fee). Authors can preselect referral at submission, so a paper JAMA does not accept can be referred, with reviewers' comments if available, to a JAMA Network specialty journal and/or JAMA Network Open. JAMA Network Open accepts a broader range of research at a higher acceptance rate.

The Lancet's editorial mandate: improve global health with an equity lens. The Lancet thinks in terms of populations, health systems, and international policy, not just individual patient decisions.

The Lancet's sweet spot:

• Multi-country randomized trials where geographic variation is part of the finding

• Global Burden of Disease analyses and population-level epidemiology

• Health policy research with implications across health systems

• Research addressing health inequities, particularly in low- and middle-income countries

• Studies where the significance grows when you widen the frame from one country to many

The Lancet's fast-track pathway. For randomised controlled trials, The Lancet's editors say they will decide within 48 hours whether a submission can be prioritised, that the initial decision will typically be reached within 2 weeks, and that, if accepted, online publication normally occurs within 28 days of submission.

The Lancet family ecosystem. The Lancet has 24 specialty journals (Lancet Oncology IF 33.7, Lancet Infectious Diseases IF 29.4, Lancet Digital Health IF 25.5, Lancet Global Health IF 22.5, etc.). Papers that are too narrow for the flagship often fit a Lancet specialty journal. The editorial relationship means desk-rejected papers can sometimes be redirected within the family.

For US clinical practice papers. If the paper's primary audience is US physicians and the clinical decision is broad (not specialty-bound), JAMA is the natural home. A comparative effectiveness trial of two common treatments, tested in US settings, with implications for general practice, that's a JAMA paper.

For health-services and implementation research. JAMA has a genuine editorial interest in how evidence reaches patients. Implementation science, disparities research, and health-system efficiency studies have a clearer path at JAMA than at The Lancet, which tends to want population-scale consequence.

For statistical rigor as a selling point. If your trial's statistical design is the strongest aspect of the paper, JAMA's requirement that analyses match the protocol and statistical analysis plan works in your favor. A clean, pre-registered trial with a perfectly executed statistical analysis plan is a JAMA strength.

For international and multi-country work. If the paper's significance depends on geographic variation, cross-system comparison, or global health framing, The Lancet's editorial mandate is built for it. A trial conducted in 15 countries showing different treatment effects by health-system context is a Lancet paper, not a JAMA paper.

For global health equity. The Lancet's commitment to health equity and LMIC research is genuine and editorial, not performative. Research on maternal mortality in sub-Saharan Africa, infectious disease interventions in South Asia, or non-communicable disease burden across income levels has a natural home at The Lancet.

For eligible randomised trials on its fast-track pathway. The Lancet promises a prioritisation decision within 48 hours, an initial decision typically within 2 weeks, and online publication normally within 28 days of submission if accepted. JAMA also runs a rapid route, JAMA-EXPRESS, for major clinical trials and other original research with immediate or public health importance.

For IF-sensitive career decisions. At 88.5 vs 55.0, The Lancet's IF advantage is real for grant applications and promotion cases where committees use IF as a proxy.

Authors send a strong but mainly US clinical-decision paper to The Lancet because the IF is higher. The paper gets desk-rejected because the editors don't see international consequence, the paper is excellent but reads as relevant to American practice, not global health.

The reverse mistake: a genuinely international study gets framed too narrowly for JAMA because the authors are more familiar with the brand. The paper reads like a US clinical study when it should be positioned as a multi-system finding.

The test: Read your first paragraph. If it's strongest when it says what a general physician should do differently, JAMA. If it's strongest when it explains what changes across countries, systems, or populations, The Lancet.

• The paper answers a broad clinical question relevant to practicing physicians

• The strongest framing is "here's what you should do differently in your practice"

• Health-services, implementation, or disparities research is the core

• The study is US-based but generalizable

• Your statistical design is impeccable and your analyses match your protocol and statistical analysis plan

• The paper has clear international or multi-country significance

• The strongest framing is "here's what changes across health systems and populations"

• Global health, health equity, or cross-system policy is the core

• The study's importance grows when you widen the geographic frame

• You have a randomised controlled trial that qualifies for the fast-track pathway

Neither journal publishes a desk-rejection rate. JAMA says it accepts 10% of submissions (4% of research manuscripts) and rejects manuscripts with insufficient priority promptly; The Lancet says its overall acceptance rate is about 5% and that many papers are turned away on in-house assessment alone. Understanding why helps you avoid it.

JAMA desk rejection patterns: Papers that are too narrow for a general medical audience (belongs in a JAMA specialty journal). Papers where the clinical decision isn't clear, the study is interesting but doesn't change what a physician does. Papers with statistical analysis plan inconsistencies that the editorial team catches immediately.

Lancet desk rejection patterns: Papers without international or population-level consequence. Papers where the "global framing" is in the cover letter but not in the data, the study was done in one country and the international relevance is asserted rather than demonstrated. Papers that are strong clinical research but don't carry policy implications beyond the clinical decision.

The fastest way to avoid desk rejection at either journal: run a JAMA vs. Lancet scope check that scores journal fit and desk-reject risk before you submit. It takes about two to three minutes.

Before choosing between JAMA and The Lancet, a JAMA vs. Lancet scope check can assess whether your manuscript reads as a clinical-decision paper (JAMA) or a global-consequence paper (The Lancet). The scan takes about two to three minutes and is free.

A JAMA vs. Lancet scope check can help you identify the right target before committing to a submission cycle.